

## DRUG UTILIZATION REVIEW BOARD

October 17, 2012

James C. Kirkpatrick State Information Center, 600 West Main Street, Jefferson City MO

### DUR BOARD MEMBERS PRESENT

Susan Abdel-Rahman, PharmD  
Jennifer Passanise, ANCC-BC, FNP  
Sandra Bollinger, PharmD  
Stacy Mangum, Pharm D  
Glenn Talboy, MD  
Ginger Nicol, MD  
Randy Beckner, PharmD  
Charlene Heyde, RPh

### DUR BOARD MEMBERS ABSENT

Kenneth Haller, MD  
Kirk Nelson, MD

### MHD STAFF PRESENT

Mark Roaseau, RPh, Clinical Pharmacist  
Allison Lauf, RN  
Jennifer Willmeno, Sr. Office Support Assistant  
Marsha Kelly, Sr. Office Support Assistant  
Ashley Wilson, DUR Coordinator  
Andrew Haslag, Fiscal Manager  
Jenna Twehus, RN  
Angela Wilson, Pharmacy Unit Supervisor  
Mary Heet, RN

### CONTRACTED STAFF PRESENT

Jennifer Kemp-Cornelius, PharmD, Xerox  
Rick Pope, PharmD, First Health Services  
Katie Wilbers, Clinical Pharmacist, Xerox  
Josh Moore, Clinical Pharmacist, Xerox  
Ami Patel, Clinical Pharmacist, Xerox

### OTHERS IN ATTENDANCE

Eric Blake, Merck  
Hank Lavellet, Forest  
Brian Chronister, PBRMC  
Dave Sprat, BMS  
Karla Schafer, BI  
Dean Groth, Pfizer

Geri Roling, WIPRO/IFOX  
Eric Gardner, Vertex Pharma  
Mike Krug, Sunovion  
Robert Pearce, TEVA  
Mike Kloos, Pfizer

Scott Edelhauser, Alcon  
Joe Summers, Novo Nordisk  
Kiernan Keating, Takeda  
Suzanne Goot, Abbott  
Chet Steckler, Purdue

Jim Baumann, Pfizer  
Shefali Patel, Wipro/Ifox  
Terry McCurren, Otsuka  
Lainie Giovanini, BI  
Joe Shaker, Genzyme

\*Many names on the sign in sheet were illegible. Sign in sheet on file for review.

<b>Welcome, Introductions and Opening Remarks</b>	Acting Chairman, Susan Abdel-Rahman, PharmD, called the meeting to order at approximately 10:10 a.m. A quorum was established. Mark Roaseau, facilitated the meeting on behalf of the MO HealthNet Division (MHD). No introductions or announcements were made.
<b>Minutes Approval</b>	Minutes of the April 18, 2012 meeting were reviewed and approved as submitted.
<b>Pharmacy Program/Budget Update</b>	Andrew Haslag provided a budget update. Mr. Haslag stated that there weren't a lot of pharmacy issues for the Fiscal Year 13 budget. A significant amount of generic savings have been booked as several high profile drugs should be going generic over the next few months. In the past, the pharmacy benefit for the Blind Pension eligibles was in the MHD budget. Mr. Haslag stated the funding for this group has been moved out of the MHD budget, but MHD is still administering the program. Rhonda Driver reviewed the 5010 D.0 transaction change that went into effect for the entire nation on January 1, 2012; it is a CMS mandate. Ms. Driver stated that dedicated outreach has been done for at least two and half months to work with systems and software vendors to make sure that they are ready. From a MO HealthNet perspective, June 30 is the last day to send transactions using the old standard. Mark Roaseau discussed the ICD-10 conversion and stated that CMS is making a site visit in July with regards to ICD-10. Ms. Driver stated that there is a lot of code to remediate to prepare for the implementation to ICD-10. Ms. Driver also stated that the coding is hard and fast in MMIS and we have to figure out how to define some of those codes again so that everyone codes it the right way. Ms. Driver stated that the Health Home Initiative is still moving forward.
<b>Review of Prior Authorization Meeting:</b>	Copies of the agenda and draft minutes, including public hearing, from the June 21, 2012 <i>Drug Prior Authorization Committee Meeting</i> were included in the members' meeting packet.
<b>Voting on a Chair</b>	Susan Abdel-Rahman nominated Sandra Bollinger. Sandra Bollinger nominated Susan Abdel-Rahman. Susan Abdel-Rahman nominated Stacy Mangum. Susan Abdel-Rahman received four votes, Stacy Mangum received two votes. Sandra Bollinger received one vote. Susan Abdel-Rahman is the new DUR Board Chair.
<b>Implementation Schedule</b>	An updated copy of the <i>Proposed Implementation Schedule for Edits</i> , including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The schedule had been updated with all edits approved at the last quarter's meetings which included and annual PDL implementation. This schedule may be found on the MHD web page at <a href="http://dss.missouri.gov/mhd/cs/pharmacy/pdf/impsched.pdf">http://dss.missouri.gov/mhd/cs/pharmacy/pdf/impsched.pdf</a>
<b>New Drug Review</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> - Drug monographs were available for review at <a href="http://www.heritage-info.com/mocaidrx">http://www.heritage-info.com/mocaidrx</a> for all new products reviewed this quarter (Identified by First Data Bank in January, February, and March 2012). A listing of products recommended for open access, clinical edit, as a PDL product or for continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout (see meeting packet) to all attending. Ms. Driver reviewed</li> </ul>

	<p>the MHD recommendations for products whose review was completed this quarter.</p> <ul style="list-style-type: none"> <li>• <b>Decision</b> – In the interest of time the Board agreed to block these and the Preferred Drug List (PDL) recommendations into one inclusive vote, pulling out any issues that might require separate discussion. New Drug recommendations were included in this block vote and approved as submitted. (See Roll Call Vote)</li> </ul>
<b>Preferred Drug List (PDL)</b>	<p>Products and classes under review this quarter have existing contracts through June 30, 2012. Recommended changes to the edits were bolded for easy identification.</p>
<b>ADHD Therapy-Clinical Edit</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> –Ms. Driver reviewed the addition of dosing limitations for pediatric and adult doses.</li> <li>• <b>Decision</b> – The Committee voted to accept this edit as presented. (See Roll Call Vote)</li> </ul>
<b>Botulinium Toxin-Clinical Edit</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the approval and denial criteria, including the new indication for Botox.</li> <li>• <b>Decision</b> –The Committee voted to accept this edit and review the suggestion. (See Roll Call Vote)</li> </ul>
<b>PDL Annual Review:</b>	
<b>GLP-1 Receptor Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – The Committee voted to accept this edit as presented. (See Roll Call Vote)</li> </ul>
<b>Amylin Analogs</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – The Committee voted to accept this edit as presented. (See Roll Call Vote)</li> </ul>
<b>Cox II Inhibitors</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – The Committee voted to accept this edit as presented. (See Roll Call Vote)</li> </ul>
<b>Hepatitis C Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents, noting that both protease inhibitors are recommended for preferred status.</li> <li>• <b>Decision</b> – The Committee voted to accept this edit as presented. (See Roll Call Vote)</li> </ul>
<b>Proton Pump Inhibitors</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – The Committee voted to accept this edit as presented. (See Roll Call Vote)</li> </ul>
<b>Topical Androgenic Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing the preferred and non-preferred agents.</li> <li>• <b>Decision</b> – The Committee voted to accept this edit as presented. (See Roll Call Vote)</li> </ul>
<b>Beta Blockers</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – The Committee voted to accept this edit as presented. (See Roll Call Vote)</li> </ul>
<b>Calcium Channel Blockers: Non-Dihydropyridine</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> </ul>

	<ul style="list-style-type: none"> <li>• <b>Decision</b> – The Committee voted to accept this edit as presented. (See Roll Call Vote)</li> </ul>
<b>Calcium Channel Blockers: Dihydropyridine</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – The Committee voted to accept this edit as presented. (See Roll Call Vote)</li> </ul>
<b>Calcium Channel Blockers/ ARB Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria documents, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – The Committee voted to accept this edit as presented. (See Roll Call Vote)</li> </ul>
<b>Dipeptidyl Peptidase-4 Inhibitor</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria documents, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – The Committee voted to accept this edit as presented. (See Roll Call Vote)</li> </ul>
<b>Onychomycosis Antifungal Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria documents, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – The Committee voted to accept this edit as presented. (See Roll Call Vote)</li> </ul>
<b>Ribavirins</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents.</li> <li>• <b>Decision</b> – The Committee voted to accept this edit as presented. (See Roll Call Vote)</li> </ul>
<b>Topical Immunomodulators</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver stated that there is no change recommended for this class.</li> <li>• <b>Decision</b> – The Committee voted to accept this edit as presented. (See Roll Call Vote)</li> </ul>
<b>Preferred Drug List Announcement</b>	A handout of therapeutic categories to be considered for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page.
<b>Xerox Update</b>	Jennifer Kemp-Cornelius, PharmD, reviewed the call center statistics for Skeletal Muscle Relaxants and Fibromyalgia. Ms. Kemp-Cornelius went over the approval and denial criteria for both Skeletal Muscle Relaxants and Fibromyalgia. She also reviewed the per member-per month costs for agents that are most prescribed. Ms. Kemp-Cornelius asked if there were any edits that the Board was interested in looking at utilization for at the next meeting. She stated that her team would look at the short-acting narcotics for the September 20, 2012, meeting.
<b>Program Utilization: Top 25 Drugs by Cost</b>	Jennifer Kemp-Cornelius, PharmD, reviewed the Top 25 Drugs by Cost and provided two forms, one showing by Paid Amount and one by Claims.
<b>Call Center Statistics/ CyberAccess Reports</b>	A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity was shared. Ms. Kemp-Cornelius reviewed how many sites/physical locations are trained and have access to CyberAccess and how many prescribers and active users CyberAccess has. She stated that the psychology and counseling sites would be the next group that Xerox would focus on would making changes in CyberAccess to allow them to request their prior authorizations through Cyber rather than calling in or sending a fax. She also stated that during the month of May, a major change was made to the medical pre-certification pages and as a result, they activity was not getting logged so they would work on getting that fixed.

<b>Adjourn</b>	The DUR Board went into Executive Session for the sole purpose of discussing individual participant specific medical information. At the conclusion of these discussions the group adjourned entertaining no further business, actions or motions. (See attached roll call vote). The next meeting is scheduled for October 17, 2012
----------------	--

**Roll Call Votes – October 17, 2012**

<b>Member</b>	<b>Meeting Minutes</b>	<b>Clinical Edit Block Vote</b>	<b>PDL Block Vote</b>	<b>Closed Session</b>	<b>Adjourn</b>
Susan Abdel-Rahman	Y	Y		Y	Y
Charlene Heyde	Y	Y		Y	Y
Sandra Bollinger	Y	Y		Y	Y
Kenneth Haller	A	A		A	A
Glenn Talboy	Y	Y		Y	Y
Jennifer Passanise	Y	Y		Y	Y
Stacy Mangum	Y	Y		Y	Y
Kirk Nelson	A	A		A	A
Ginger Nicol	Y	Y		Y	Y
Randy Beckner	Y	Y		Y	Y

**EXECUTIVE SESSION**

October 17, 2012

**DUR BOARD MEMBERS PRESENT**

Susan Abdel-Rahman, PharmD  
Jennifer Passanise, ANCC-BC, FNP  
Sandra Bollinger, PharmD  
Stacy Mangum, Pharm D  
Glenn Talboy, MD  
Ginger Nicol, MD  
Randy Beckner, PharmD  
Charlene Heyde, RPh

**DUR BOARD MEMBERS ABSENT**

Kenneth Haller, MD  
Kirk Nelson, MD

**MHD STAFF PRESENT**

Mark Roaseau, RPh, Clinical Pharmacist  
Allison Lauf, RN  
Jennifer Willmeno, Sr. Office Support Assistant  
Marsha Kelly, Sr. Office Support Assistant  
Ashley Wilson, DUR Coordinator  
Jenna Twehus, RN  
Angela Wilson, Pharmacy Unit Supervisor  
Mary Heet, RN

**CONTRACTED STAFF PRESENT**

Jennifer Kemp-Cornelius, PharmD, Xerox  
Rick Pope, PharmD, First Health Services  
Katie Wilbers, Clinical Pharmacist, Xerox  
Josh Moore, Clinical Pharmacist, Xerox  
Ami Patel, Clinical Pharmacist, Xerox

Minutes Review	Minutes of the April Executive Session were approved as submitted
Case Reviews	Jenna Twehus, RN presented two handouts that detailed provider summary results and benchmark data for patients being prescribed large amounts of narcotics. The discussion included why these 2 patients were being prescribed high dosages and multiple narcotics. The board decided to do further research to get more information on these issues. No other issues were discussed.
Adjourn	Executive session adjourned at approximately 1:30p.m. (See roll call vote)